ClinicalTrials.gg
CompletedNCT03336450Updated Sep 14, 2021Results posted

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

A Phase 3 interventional study of SHP615 and MHOS/SHP615 in Nervous System Diseases, sponsored by Shire. Completed at 23 sites in Japan. Open to participants aged 6 Months to 216 Months. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
6 Months to 216 Months
Sex
All
01

Study summary

The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is safe and effective in children with status epilepticus (SE) (convulsive) in the community setting. This study is open-label extension for patients who completed the SHP615-301 study and who tolerated and responded to MHOS/SHP615 treatment in the hospital setting.

02

Conditions studied

  • Nervous System Diseases
03

In context

Nervous System Diseases

758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's enrollment of 3 is below the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 216 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who completed the SHP615-301 study and who tolerated and responded to treatment with MHOS/SHP615 in the hospital and/or emergency room, and are considered stable for discharge from the hospital.
  • Subjects who are greater than (>) 6 months and less than (\<) 18 years of age at the time of product administration. If the subject's exact age is not known, the subject should be excluded.
  • Parent, guardian, or legally authorized representative of the child who provides and assent (when applicable) to participate in the study after initial stabilization of the subject with SE in hospital or emergency room during the SHP615-301 study. The subject also provides informed consent prior to participation, where applicable.
  • Parent, guardian, or legally authorized representative who have received appropriate training/education and are deemed qualified by the investigator and are willing to:

    1. Properly administer MHOS/SHP615.
    2. Record seizure information and dosing of MHOS/SHP615 in a subject diary (including time of seizure onset, type of seizure, time necessary to administer MHOS/SHP615, time between MHOS/SHP615 administration to seizure cessation, etc.)
    3. Follow the necessary instructions to secure the safety of the subject.
  • Subjects who experience generalized tonic-clonic SE with seizures accompanied by loss of consciousness with any of the following characteristics persistent at the time of study drug administration:

    1. Currently presenting with seizure (convulsive) activity and 3 or more convulsions within the preceding hour
    2. Currently presenting with seizure (convulsive) and 2 or more convulsions in succession without recovery of consciousness.
    3. Currently presenting with a single seizure (convulsive) persisting greater than or equal to (>=) 5 minutes.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, suspected to be pregnant, or nursing.
  • Subjects with major trauma, not necessarily restricted to the head, as the cause of the seizure.
  • Subjects with known or suspected recurrent seizures due to illegal drug or alcohol withdrawal.
  • Subjects with seizures due to illegal drug or acute alcoholic intoxication.
  • Subjects with seizures of psychogenic origin.
  • Subjects with seizures due to severe encephalitis or meningitis, as determined by the PI
  • Subjects with known history of , nonresponsiveness or to benzodiazepines (that is (ie), respiratory depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea, glaucoma with closed angle, or use of concomitant drugs determined by the investigator to have a contraindication to the use of benzodiazepines.)
  • Subjects with a known history of benzodiazepine abuse.
  • Subjects who have not responded to previous administrations of midazolam systemic therapies, including MIDAFRESA and/or DORMICUM.
  • Subjects who need emergent surgical intervention and general anesthesia/intubation.
  • Subjects who have been receiving (HIV) protease inhibitors or HIV reverse transcriptase inhibitors.
  • Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the healthcare provider.
  • Have used an product or been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.
  • Subject has prior placement of a vagus nerve stimulator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    SHP615

    Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram \[mg/kg\] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.

    Drug: SHP615 · Drug: MHOS/SHP615

Interventions

  • DrugSHP615

    SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).

    Also known as: MHOS, Midazolam hydrochloride oromucosal solution

  • DrugMHOS/SHP615

    Drug page: Midazolam

    MHOS/SHP615

06

What researchers measure

Primary outcomes

  1. Efficacy: Number of Participants With Therapeutic Success

    Therapeutic success was defined as cessation of visible seizure activity within 10 minutes and sustained absence of visible seizure activity for 30 minutes following a single dose of SHP615 without the need for additional rescue medication. Number of participants with therapeutic success were reported.

    Time frame: From start of study drug administration up to 30 minutes post-dose

  2. Safety: Number of Participants With Respiratory Depression

    Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to \<92 percent (%) measured up to 24 hours post-dose (i.e., \<92% on room air for 2 minutes or more after dosing while monitoring \[per healthcare setting protocol and/or the clinical judgment of the physician\]. ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.

    Time frame: Up to 24 hours post-dose

Secondary outcomes

  1. Efficacy: Number of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4, and 6 Hours

    Number of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.

    Time frame: From start of study drug administration up to 1, 4, and 6 hours post-dose

  2. Efficacy: Time to Resolution of Seizures (Convulsions)

    Time to resolution of seizures (convulsions) was calculated as time from SHP615 administration to the end of the initial seizure or administration of rescue anticonvulsant medication, whichever occurs first. The initial seizure refers to the seizure which triggered the use of the IP. Participant wise data was reported for this outcome.

    Time frame: From start of study drug administration up to follow-up (Day 8)

  3. Efficacy: Time to Recovery of Consciousness

    Time to recovery of consciousness in minutes was calculated only for participants who lost consciousness pre-dose as time from SHP615 administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Participant wise data was reported for this outcome.

    Time frame: From start of study drug administration up to follow-up (Day 8)

  4. Efficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP615

    Percentage of participants who required additional anticonvulsant medication for ongoing SE according to the participating hospital protocol or guideline, 10 minutes after the administration of SHP615 were reported.

    Time frame: 10 minutes post-dose

  5. Efficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP615

    Treatment failure/non-responder was defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline 10 minutes after administration of SHP615 was reported.

    Time frame: 10 minutes post-dose

  6. Safety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)

    TEAEs was defined as adverse events (AEs) whose onset occurs, severity worsens or intensity increases on or after the date of SHP615 administration. Number of participants with aspiration pneumonia identified as TEAEs were reported.

    Time frame: From start of study drug administration up to follow-up (Day 8)

  7. Safety: Number of Participants Analyzed for Sedation or Agitation Measured by the Riker Sedation-Agitation Scale

    Sedation-Agitation was assessed, using the "Riker Sedation-Agitation Scale" (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Number of participants analyzed for sedation or agitation measured by the riker sedation-agitation scale were reported.

    Time frame: 1, 4, 6, and 24 hours post-dose

  8. Safety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)

    TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Buccal cavity was examined for redness, inflammation and ulceration. Number of participants with buccal irritation reported as TEAEs were reported.

    Time frame: Up to 6 hours post-dose

  9. Safety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Number of participants with TEAEs were reported.

    Time frame: From start of study drug administration up to follow-up (Day 8)

  10. Safety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs

    Vital sign assessments included blood pressure, pulse, respiratory rate and body temperature. Any change in vital signs which were deemed clinically significant by the investigator were recorded as TEAEs.

    Time frame: From start of study drug administration up to 24 hours post-dose

  11. Safety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs

    Clinical laboratory evaluations included biochemistry, endocrinology, hematology and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.

    Time frame: From start of study drug administration up to 24 hours post-dose

  12. Safety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs

    12-lead ECG were evaluated. Any change in ECG assessments which are deemed clinically significant by the investigator were reported as TEAEs.

    Time frame: From start of study drug administration up to 24 hours post-dose

  13. Safety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting

    Oxygen saturation is the amount of oxygen that is in bloodstream and is measured as the percentage of blood hemoglobin that is carrying oxygen. Normal oxygen saturation levels are considered to be 95-100 percent; low oxygen saturation values indicate worse disease. Oxygen saturation was measured and recorded on room air. The investigator recorded the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered during hospital setting. Percentage of participants with normal oxygen saturation values collected during hospital setting were reported.

    Time frame: 0.5, 1, 4, 6 and 24 hours post-dose

07

Results

Posted Sep 14, 2021

Participant flow

The study was conducted at 27 centers in Japan between 23 April 2018 (first participant first visit) and 13 October 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneSHP615
Started3
Completed3
Not completed0

Outcome measures

PrimaryEfficacy: Number of Participants With Therapeutic Success

Therapeutic success was defined as cessation of visible seizure activity within 10 minutes and sustained absence of visible seizure activity for 30 minutes following a single dose of SHP615 without the need for additional rescue medication. Number of participants with therapeutic success were reported.

Time frame:
From start of study drug administration up to 30 minutes post-dose
Reported as:
Count of participants · Participants
Efficacy: Number of Participants With Therapeutic Success
ParticipantsSHP615
Efficacy: Number of Participants With Therapeutic Success3
SecondaryEfficacy: Number of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4, and 6 Hours

Number of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.

Time frame:
From start of study drug administration up to 1, 4, and 6 hours post-dose
Reported as:
Count of participants · Participants
Efficacy: Number of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4, and 6 Hours
ParticipantsSHP615
Sustained absence for at least 1 hour3
Sustained absence for at least 4 hour0
Sustained absence for at least 6 hour1
SecondaryEfficacy: Time to Resolution of Seizures (Convulsions)

Time to resolution of seizures (convulsions) was calculated as time from SHP615 administration to the end of the initial seizure or administration of rescue anticonvulsant medication, whichever occurs first. The initial seizure refers to the seizure which triggered the use of the IP. Participant wise data was reported for this outcome.

Time frame:
From start of study drug administration up to follow-up (Day 8)
Reported as:
Number · Minutes
Efficacy: Time to Resolution of Seizures (Convulsions)
MinutesSHP615
Participant 11
Participant 22
Participant 35
SecondaryEfficacy: Time to Recovery of Consciousness

Time to recovery of consciousness in minutes was calculated only for participants who lost consciousness pre-dose as time from SHP615 administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Participant wise data was reported for this outcome.

Time frame:
From start of study drug administration up to follow-up (Day 8)
Reported as:
Number · Minutes
Efficacy: Time to Recovery of Consciousness
MinutesSHP615
Participant 14
Participant 2143
Participant 35
SecondaryEfficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP615

Percentage of participants who required additional anticonvulsant medication for ongoing SE according to the participating hospital protocol or guideline, 10 minutes after the administration of SHP615 were reported.

Time frame:
10 minutes post-dose
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP615
Percentage of participantsSHP615
Efficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP6150
SecondaryEfficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP615

Treatment failure/non-responder was defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline 10 minutes after administration of SHP615 was reported.

Time frame:
10 minutes post-dose
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP615
Percentage of participantsSHP615
Efficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP6150
PrimarySafety: Number of Participants With Respiratory Depression

Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to \<92 percent (%) measured up to 24 hours post-dose (i.e., \<92% on room air for 2 minutes or more after dosing while monitoring \[per healthcare setting protocol and/or the clinical judgment of the physician\]. ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.

Time frame:
Up to 24 hours post-dose
Reported as:
Count of participants · Participants
Safety: Number of Participants With Respiratory Depression
ParticipantsSHP615
Safety: Number of Participants With Respiratory Depression0
SecondarySafety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)

TEAEs was defined as adverse events (AEs) whose onset occurs, severity worsens or intensity increases on or after the date of SHP615 administration. Number of participants with aspiration pneumonia identified as TEAEs were reported.

Time frame:
From start of study drug administration up to follow-up (Day 8)
Reported as:
Count of participants · Participants
Safety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)
ParticipantsSHP615
Safety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)0
SecondarySafety: Number of Participants Analyzed for Sedation or Agitation Measured by the Riker Sedation-Agitation Scale

Sedation-Agitation was assessed, using the "Riker Sedation-Agitation Scale" (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Number of participants analyzed for sedation or agitation measured by the riker sedation-agitation scale were reported.

Time frame:
1, 4, 6, and 24 hours post-dose
Reported as:
Count of participants · Participants
Safety: Number of Participants Analyzed for Sedation or Agitation Measured by the Riker Sedation-Agitation Scale
ParticipantsSHP615
Participant with unarousable0
Participant with very sedated1
Participant with sedated1
Participant with calm and cooperative3
Participant with agitated1
Participant with very agitated0
Participant with dangerous agitation0
SecondarySafety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)

TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Buccal cavity was examined for redness, inflammation and ulceration. Number of participants with buccal irritation reported as TEAEs were reported.

Time frame:
Up to 6 hours post-dose
Reported as:
Count of participants · Participants
Safety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)
ParticipantsSHP615
Safety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)0
SecondarySafety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Number of participants with TEAEs were reported.

Time frame:
From start of study drug administration up to follow-up (Day 8)
Reported as:
Count of participants · Participants
Safety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSHP615
Safety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)2
SecondarySafety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs

Vital sign assessments included blood pressure, pulse, respiratory rate and body temperature. Any change in vital signs which were deemed clinically significant by the investigator were recorded as TEAEs.

Time frame:
From start of study drug administration up to 24 hours post-dose
Reported as:
Count of participants · Participants
Safety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs
ParticipantsSHP615
Safety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs0
SecondarySafety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs

Clinical laboratory evaluations included biochemistry, endocrinology, hematology and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.

Time frame:
From start of study drug administration up to 24 hours post-dose
Reported as:
Count of participants · Participants
Safety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs
ParticipantsSHP615
Safety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs0
SecondarySafety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs

12-lead ECG were evaluated. Any change in ECG assessments which are deemed clinically significant by the investigator were reported as TEAEs.

Time frame:
From start of study drug administration up to 24 hours post-dose
Reported as:
Count of participants · Participants
Safety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs
ParticipantsSHP615
Safety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs0
SecondarySafety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting

Oxygen saturation is the amount of oxygen that is in bloodstream and is measured as the percentage of blood hemoglobin that is carrying oxygen. Normal oxygen saturation levels are considered to be 95-100 percent; low oxygen saturation values indicate worse disease. Oxygen saturation was measured and recorded on room air. The investigator recorded the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered during hospital setting. Percentage of participants with normal oxygen saturation values collected during hospital setting were reported.

Time frame:
0.5, 1, 4, 6 and 24 hours post-dose
Reported as:
Number · Percentage of participants
Safety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting
Percentage of participantsSHP615
Safety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting100

Adverse events

Collected over From start of study drug administration up to follow-up (Day 8). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHP6150/3 (0%)1/3 (33.3%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventSHP615
Febrile convulsionNervous system disorders1/3
Most frequent other events
Most frequent other events
EventSHP615
SomnolenceNervous system disorders1/3
NauseaGastrointestinal disorders1/3
VomitingGastrointestinal disorders1/3
Upper respiratory tract infectionInfections and infestations1/3

Baseline characteristics

Safety set consisted of all participants who had received a single dose of Investigational product (IP), regardless of whether the study drug administration was documented to be complete or not on the study drug administration electronic case report form (eCRF).

Age, Continuous
Age, Continuous(Years)SHP615
Mean5.07 ± 1.570
Sex: Female, Male
Sex: Female, Male(Participants)SHP615
Female1
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SHP615
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHP615
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

23 sites
  • Yamanashi Prefectural Central Hospital
    Kofu, Fujimi 400-8506, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • NHO Minami-Okayama Medical Center
    Okayama, Okayama Prefecture 701-0304, Japan
  • Tokyo Women's Medical University Yachiyo Medical Center
    Yachiyo, Owada Shinden 276-8524, Japan
  • Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, Shizuoka Prefecture 420-8688, Japan
  • Fukuoka Children's Hospital(NW)
    Fukuoka, 813-0017, Japan
  • Gifu Prefectural General Medical Center
    Gifu, 500-8717, Japan
  • NHO Hokkaido Medical Center
    Hokkaidō, 063-0005, Japan
  • Kumamoto Saishunso National Hospital
    Kumamoto, 861-1196, Japan
  • NHO Nagasaki Medical Center
    Nagasaki, 856-8562, Japan
  • NHO Nishi Niigata Chuo National Hospital
    Niigata, 950-2085, Japan
  • Aichi Children's Health and Medical Center(NW)
    Obu, 474-8710, Japan
  • Okayama University Hospital
    Okayama, 700-0914, Japan
  • Nakano Children's Hospital
    Osaka, 535-0022, Japan
  • Osaka Women's and Children's Hospital(NW)
    Osaka, 594-1101, Japan
  • Jichi Children's Medical Center Tochigi
    Saitama-shi, 330-8503, Japan
  • Saitama Children's Medical Center(NW)
    Saitama, 330-8777, Japan
  • Osaka University Hospital
    Suita, 565-0871, Japan
  • Tokyo Women's Medical University Hospital
    Tokyo, 162-8666, Japan
  • National Center Hospital, NCNP
    Tokyo, 187-0031, Japan
  • Tottori University Hospital
    Tottori, 683-8504, Japan
  • Osaka University Hospital
    Yamadaoka, 565-0871, Japan
  • Kanagawa Children's Medical Center(NW)
    Yokohama, 232-0066, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · www.shiretrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Oct 2020, 29 months.

Results were first posted in Sep 2021, 11 months after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Nervous System Diseases, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 29 months is below that.

Counting every sponsor, half of 40 studies reached it within 42 months; a quarter within 28 and three quarters within 55.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 8, 2017
StartActual
Apr 23, 2018
Primary completionActual
Oct 13, 2020
CompletionActual
Oct 13, 2020
Results first posted
Sep 14, 2021
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03336450
Lead sponsor
Shire
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2017
Start date
Apr 23, 2018
Primary completion
Oct 13, 2020
Completion
Oct 13, 2020
Results posted
Sep 14, 2021
Last update
Sep 14, 2021

Study contacts

Study Director
study director · Takeda Development Center Americas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion